Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

NCT05309187 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult

Interventions

BIOLOGICAL: IO-202
BIOLOGICAL: IO-202 + pembrolizumab combination therapy
BIOLOGICAL: RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types

Sponsor

Immune-Onc Therapeutics